🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For us ‘hope’ as a strategy for cancer care was not an option. Read our story here digistain.co.uk/our-story/ #breastcancer #patients

Proud to support #BreastCancerAwarenessMonth

To all our supporters this year, all the patients & clinicians we have worked with, and the many we plan to help in the future… …we wish you all a wonderful festive season and a healthy happy 2024.

Latest validating #research demonstrating @Digistain accurate prediction of #breastcancer recurrence risk published with Springer Nature in the Journal of Breast Cancer Research & Treatment. link.springer.com/article/10.100… #oncology #pathology #innovation

Complexly novel way to assess risk of recurrence in ER+/HER2- early breast cancer using mid-infrared spectrometer digistain It’s simple,quick & can be done locally. First data using Nottinghan series, shows it can separate patients into low vs high risk. More studies underway.

Our recently published validation of a novel and effective methodology to support therapy decisions in early breast cancer demonstrated e equivalent performance to existing solutions in over 800 patients. But radically faster and more accessible. link.springer.com/article/10.100…

We’re proud to share that our landmark clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one of the journal's top-performing articles, ranked in the 97th percentile for popularity. pmc.ncbi.nlm.nih.gov/articles/PMC11…

We were honored to host Malaysia's Health Minister, Dr. Dzulkefly Ahmad, at the Digistain lab. His visit marks a key step in advancing nationwide access to transformative breast cancer diagnostics. We look forward to driving meaningful healthcare impact together. #breastcancer

Had a great time at #SABCS2024 with our clinical board members, Dario Francescatti & Carlo Palmieri!  Excited to share our data and continue our mission to make cancer diagnostics faster and more accessible to all.  #CancerDiagnostics #Digistain #CancerResearch #Oncology

Check out our 2nd abstract poster from #SABCS2024: "Analytical Validity of the Digistain Test in the Face of Variable Fixation Times." Read the full abstract here: digistain.co.uk/wp-content/upl…

Watch Professor Charles Coombes & Dr. Hemmel Amrania discuss the future of #RiskStratification in #BreastCancer and how Digistain is making it quicker & more accessible for patients everywhere. #CancerCare #HealthTech #Oncology youtube.com/watch?v=WhxNyA…

Following our partnership with Deloitte, we had the privilege of speaking with Senior Manager Roberto Vittandi, who shared his insights on Digistain and it's potential.  We believe collaboration drives innovation, and we're excited to be on this journey together!

We’re proud to show the incredible work being done by Shawn Chong and team with dedicated doctors in Indonesia who are supporting us in our mission to help close the gap in healthcare inequalities globally by providing an accessible solution for breast cancer risk stratification.

Did you know? Digistain was incubated at Imperial College London and still runs its R&D lab there! 🔬 Founded in 1907, Imperial is a global leader in science, engineering, medicine, and business, ranked #1 in the UK and Europe, and #2 in the world (QS World Rankings 2025). 🌍🎓

A massive honour to recently host Professor Samuel Haryono from the Siloam Group Indonesia during his visit to the Digistain research lab at Imperial College London. #CancerCare #PrecisionMedicine #Digistain #MedicalResearch #GlobalHealth #CancerDiagnostics

This World Cancer Day 2025, we proudly reaffirm our commitment to transforming cancer care through innovation and compassion.

Delighted to have Dr. Mel Valerie Cruz-Ordinario present to doctors at St. Luke’s Medical Center Quezon City, Philippines, sharing her specialist insight on the benefits of Digistain for precision risk stratification in breast cancer patients.

We're excited to share that Digistain is now being used by patients covered by one of the top four health insurers in the U.S. A big thank you to our incredible team, partners, and supporters who make this progress possible! #CancerDiagnostics #PrecisionMedicine

We’re excited to highlight some of the key features of the Digistain test that could make a real difference for you or your patients. To learn more about how Digistain could help, visit our website: digistain.co.uk #BreastCancerAwareness #RiskStratification #CancerCare

Dr. Hemmel Amrania, CEO of Digistain, will be delivering a keynote at the AI4Health.Cro Consortium Annual Conference today, April 8th, 2025, at the Hotel Zonar, Zagreb.  #AI4Health #CancerDiagnostics #MedTech #Oncology #AI #HealthcareInnovation #BreastCancer #Zagreb #Digistain